| Course | NSG 520 Pathophysiology and Pharmacology |
|---|---|
| Unit | Unit 8 |
| Paper type | Foundational sciences portfolio |
| Length | About 1,090 words, 6 pages |
| Format | APA 7 student paper |
| School | Herzing University |
| Program | MSN |
| Updated | October 2026 |
Free sample paper for NSG 520 Unit 8
Foundational Sciences Portfolio for One Patient With Diabetic Kidney Disease: Mechanism, Handling, Selection, Monitoring, and Explanation, Each Answering the Others
Student Name
Department of Nursing, Herzing University
NSG 520: Pathophysiology and Pharmacology
Instructor Name
March 11, 2026
Foundational Sciences Portfolio for One Patient With Diabetic Kidney Disease: Mechanism, Handling, Selection, Monitoring, and Explanation, Each Answering the Others
1. Mechanism
Mrs. D., a composite woman of 68, has type 2 diabetes of 14 years' standing and a urine albumin-to-creatinine ratio that was 420 mg/g at the start of this work, with an estimated filtration rate of 38. The mechanism traced for her begins at the glucose-sodium transporter in the early tubule: in chronic hyperglycemia, the transporter reclaims more glucose and sodium, less sodium chloride reaches the macula densa, tubuloglomerular feedback dilates the afferent arteriole, angiotensin II constricts the efferent arteriole, and the glomerulus hyperfilters. Sustained pressure injures podocytes and, with glycation-related changes in the basement membrane, opens the barrier to albumin (Tonneijck et al., 2017). A second, parallel mechanism, mineralocorticoid receptor overactivation in kidney cells, drives inflammation and fibrosis independent of pressure. Every later section returns to these two mechanisms.
2. Handling Characteristics
Her estimated filtration rate, 38 at the start and 35 after the expected dip, is the characteristic that most changes how drugs behave in her. Metformin leaves the body unchanged in urine, which is why its dose was halved. Glipizide is handled by the liver, which turns it into inactive products, so her kidneys do not slow its removal, but its glucose-independent action makes hypoglycemia the concern when other agents are added; its dose was also halved. Dapagliflozin's glucose-lowering effect depends on filtration and is modest at her level, while its kidney effect does not. Finerenone's main risk, hyperkalemia, is greater because reduced filtration already limits potassium excretion. Her kidney function estimates differed by more than ten points across methods and body weights, a spread that was kept in view at every threshold.
3. Selection
Each agent in her regimen acts on a named step of the mechanism. Lisinopril reduces angiotensin II and with it efferent constriction and intraglomerular pressure. Dapagliflozin blocks the transporter where the mechanism begins, restoring feedback and reducing afferent dilation; in a large trial in chronic kidney disease, it cut the combined risk of kidney decline, kidney failure, and renal or cardiac death (Heerspink et al., 2020). Finerenone blocks the mineralocorticoid receptor in inflammatory and fibrotic pathways that the other two do not address, and in a trial of patients with type 2 diabetes already on renin-angiotensin blockade, it reduced kidney outcomes (Bakris et al., 2020). Metformin and glipizide act on glucose, at the liver and the beta cell. A GLP-1 receptor agonist has been identified as the next agent if glucose needs further lowering, because it acts at steps not yet covered and in a glucose-dependent way, and glipizide would then be stopped.
4. Monitoring
Each monitored value is tied to a mechanism or a handling characteristic. Creatinine and filtration rate: to confirm that the dip after dapagliflozin was the expected fall in glomerular pressure and has stabilized. Albumin-to-creatinine ratio: the direct measure of the barrier the treatment protects; it is down from 420 at baseline to 290 mg/g now. Potassium: from the collecting duct, where both lisinopril and finerenone reduce potassium secretion; its rise of 0.3 mmol/L after finerenone holds the finerenone dose at 10 mg. Bicarbonate: for metabolic acidosis of kidney disease, which would also be worsened by metformin accumulation. Hemoglobin: for anemia of kidney disease, which also affects how her glycated hemoglobin should be read. Parathyroid hormone, phosphate, and vitamin D: for mineral and bone disorder. The schedule follows the drugs' known effects: kidney function and potassium four weeks after any change, then every three months.
5. Explanation to the Patient
Mrs. D. was given a plain language explanation of dapagliflozin that kept the mechanism intact: the tube after each filter takes back sugar and salt; a sensor farther down notices less salt and opens the filter wider; the medicine blocks the reabsorption so the sensor turns the pressure back down. The explanation warned in advance about the expected dip in her kidney number, which is the point at which patients most often stop the drug in fear, and gave sick-day instructions. Her teach-back, describing in her own words how the drug lowers the strain on her filters, was accurate.
How the Parts Answer One Another
The mechanism explains why three different drugs protect her kidneys, and the handling section explains why each was dosed as it was. The selection section places every drug on a step of the mechanism. The monitoring section watches the steps that the drugs change and the risks that follow from the same receptors, and the explanation to the patient carries the mechanism into words she can use. A change in one part would require changes in the others: if her potassium rose further, the finerenone decision in the selection section, the potassium schedule in the monitoring section, and the diet advice in the explanation would all change together. Guidance for diabetes in chronic kidney disease describes this layered approach, with renin-angiotensin blockade and a sodium-glucose cotransporter 2 inhibitor as the foundation and additional agents added for residual risk (Rossing et al., 2022).
What the Portfolio Would Change if She Became Acutely Ill
The value of linking the parts shows most clearly in a scenario. Suppose Mrs. D. develops vomiting and diarrhea from a stomach virus and cannot keep fluids down. The mechanism section predicts that her kidneys, already dependent on reduced but carefully balanced glomerular pressure, will lose filtration quickly with dehydration, especially because lisinopril prevents the efferent arteriole from constricting to compensate. The handling section predicts that metformin will accumulate as filtration falls and that potassium will rise. The selection section identifies which drugs to hold: dapagliflozin, because of the ketoacidosis risk and further volume loss; metformin, because of accumulation; lisinopril and finerenone, because of kidney function and potassium. The monitoring section calls for creatinine and potassium within a day or two if she is unwell for more than twenty-four hours. And the explanation she received already told her to stop dapagliflozin and call. One scenario draws on all five sections, which is the test of whether they were built to fit together.
What Remains Uncertain
Whether her albuminuria will continue to fall, and at what rate her filtration will decline, cannot be known yet. The combination of three kidney-protective drugs is supported by trials of each drug added to the others, not by a trial of all three together from the start. Her anemia has not yet been explained, and iron studies are pending. The portfolio will be revisited after six months of combined treatment.
References
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., & Filippatos, G. (2020). Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. New England Journal of Medicine, 383(23), 2219-2229. https://doi.org/10.1056/NEJMoa2025845
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., Sjöström, C. D., Toto, R. D., Langkilde, A.-M., & Wheeler, D. C. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), 1436-1446. https://doi.org/10.1056/NEJMoa2024816
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., Sadusky, T., Tandon, N., Tuttle, K. R., Wanner, C., Wilkens, K. G., Zoungas, S., & de Boer, I. H. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 102(5S), S1-S127. https://doi.org/10.1016/j.kint.2022.06.008
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017). Glomerular hyperfiltration in diabetes: Mechanisms, clinical significance, and treatment. Journal of the American Society of Nephrology, 28(4), 1023-1039. https://doi.org/10.1681/ASN.2016060666
What the NSG 520 Unit 8 instructions ask for
Unit 8 asks you to compile a foundational sciences portfolio for one patient, connecting the course's units. Expect to summarize mechanism, handling, selection, monitoring and explanation, show how the parts connect, apply them to a change in the patient's condition and name what remains uncertain. Students often ask how much earlier work to include and how to show connection. Summarize each part in a paragraph and refer back to its unit. Connection means each part relies on another, such as monitoring tied to mechanism or dosing tied to handling. A scenario such as acute illness shows the parts working together under pressure. Uncertainties, such as the pace of future decline, show honest reasoning.
How the NSG 520 Unit 8 example is put together
The portfolio opens with the mechanism in a short paragraph. The handling section gives the kidney estimates that shape every dose. The selection section ties each drug to a named step of the mechanism. The monitoring section ties each lab to a reason, such as potassium for finerenone and lisinopril. The explanation section summarizes what Mrs. D. was told and how she understood it. The connection section shows how the parts depend on each other. The acute illness section applies sick-day rules derived from mechanism and handling, such as holding metformin, dapagliflozin and lisinopril during vomiting. The uncertainty section is honest about future decline. Each section points to its source unit, so the portfolio reads as one argument.
Where the points sit in the NSG 520 Unit 8 rubric
Herzing's rubric for the foundational sciences portfolio typically covers mechanism, handling, selection, monitoring, explanation, connections and application to a change. Connections between parts carry the most weight, since the portfolio exists to show integration rather than a stack of summaries. Section points reward accurate, brief summaries of each earlier unit. Application earns credit when a new scenario, such as acute illness, uses the parts together. Uncertainty points go to honest limits on prediction, such as how fast filtration may fall. Sick-day rules derived from mechanism are often credited. Consistent numbers across sections are expected, since a kidney estimate that changes between parts undermines the argument. Clear section numbering helps. KDIGO and ADA consensus guidance support the portfolio.
NSG 520 Unit 8 help: mistakes that cost points
A Unit 8 foundations portfolio most often weakens when the five earlier parts sit side by side with nothing joining them. Another frequent problem is monitoring that is not tied to mechanism. Students often skip the acute illness scenario, which is where integration shows most clearly. Uncertainties are missing, so the portfolio sounds more certain than the evidence allows. Sick-day rules are wrong or incomplete, such as forgetting the ACE inhibitor. The plain language explanation is left out. Dosing changes are not linked to handling characteristics. Kidney estimates differ between sections. Sources are dropped from the summaries. Finally, show each part answering another, because graders reward a portfolio that reads as one line of reasoning about one patient.
Get a NSG 520 Unit 8 example written to your instructions
Send the Unit 8 instructions and the rubric from your NSG 520 classroom, together with any earlier unit pieces the portfolio should build on. We write a custom example whose selection passage cites both the mechanism and the parameters above it, derives consequences from the same target, and ends with an audit. First custom sample free, returned in 24 to 48 hours.
More NSG 520 papers and MSN samples
- NSG 520 Unit 1: Cellular mechanism trace
- NSG 520 Unit 2: Dosing principle worksheet
- NSG 520 Unit 3: Two science integration case
- NSG 520 Unit 4: Receptor distribution study
- NSG 520 Unit 5: Site of action comparison
- NSG 520 Unit 6: Abnormal value interpretation table
- NSG 520 Unit 7: Plain language mechanism explainer
- NU 651 Unit 8: Organizational change dossier
- NU 715 Unit 8: Telehealth program plan
- NSG 521 Unit 8: Assessment skills portfolio
- NU 700 Unit 8: Reflection
NSG 520 Unit 8 questions, answered
Can I reuse my earlier unit work?
Most sections allow it, though the pieces have to be made to agree before they sit in one document. Redraft instead of copying, and confirm what your course permits about work handed in earlier. The joins usually need the most attention: a mechanism section written before the selection existed rarely names the step the later passage has to cite.
What does the follow-up section actually contain?
What a record would be expected to show if the reasoning held, and what it would show if the reasoning were wrong, described in general terms. It is a statement about the argument rather than a monitoring plan, and it should not carry parameters, intervals or thresholds a reader could apply to somebody.
Is a portfolio harder than the earlier units?
It is different rather than harder. The individual pieces are ones you have written before; what is new is that they have to survive being read together. Most of the effort goes into the citations between sections and into the closing audit, which is where writers arriving from other fields tend to find the actual work sits.
Where can I find a free NSG 520 Unit 8 sample paper?
Read the complete NSG 520 Unit 8 foundational sciences portfolio here at no charge, five parts connected for one patient with diabetic kidney disease. Your own NSG 520 units can be connected the same way on request.
What are sick-day rules for diabetes and kidney disease medicines?
During vomiting, diarrhea or poor intake, some drugs such as metformin, SGLT2 inhibitors and ACE inhibitors are often held to protect the kidneys. This sample applies those rules to Mrs. D. if she became acutely ill.